Immunological criteria for predicting the efficacy of therapy in patients with blastocystosis
Inter Collegas · 31.03.2026 · 1 (13)
DOI: 10.35339/ic.2026.13.1.bip ↗Kurz gefasst
Fachartikel in der Zeitschrift Inter Collegas, online erschienen am 31.03.2026. Verfasst von I.P. Bodnia. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Blastocystis is one of the most common intestinal protists in humans; its clinical significance is controversial, and no generally accepted eradication strategy exists. Infection outcomes are thought to depend on parasite subtypes, gut microbiota, and host immunity.
Aim
To determine the prognostic value of immunological parameters for the efficacy of therapy in patients with blastocystosis and to develop a prognostic algorithm on this basis. Materials and Methods. Pre-treatment immunological parameters of 300 patients with blastocystosis aged 15–54 years who received complex therapy were analyzed retrospectively. Based on the regression of clinical symptoms one month after the start of treatment, patients were divided into Group A with a good therapeutic effect (regression ≥31%; n=162) and Group B with an insufficient effect (≤30%; n=138). Prognostic coefficients for parameter gradations and informativeness (J) were calculated using the heterogeneous sequential Wald–Genkin procedure; the prognostic threshold at the 95% reliability level was ±13. The study was conducted using SPSS Statistics 29 (IBM, USA) within the author's dissertation (implementation period 2021–2026). Research Ethics. The study was conducted in accordance with the World Medical Association Declaration of Helsinki (1964–2024). All patients (for minors, their parents or legal representatives) signed informed consent to participate in the study. The research design was approved by the Ethics and Bioethics Commission of Kharkiv National Medical University (Protocol No.5 of May 05, 2021).
Results
High prognostic informativeness was found for the levels of immunoglobulin G (IgG; J=3.50), immunoglobulin A (IgA; J=2.53) and immunoglobulin M (IgM; J=2.12) and the proportion of CD8+ lymphocytes (J=1.50); moderate – for active T lymphocytes (J=0.87), CD19+ lymphocytes (J=0.79) and circulating immune complexes (J=0.73); low – for immunoglobulin E (J=0.42) and CD3+ lymphocytes (J=0.39). CD4+ lymphocytes (J=0.22) and the immunoregulatory index (J=0.06) had no prognostic value. A good effect was predicted by IgG ≥21 g/L, IgA ≥8.1 g/L and IgM ≥1.7 g/L. On the training sample (n=300), the algorithm gave 78% correct, 18% indeterminate and 4% erroneous predictions.
Conclusions
The aim of the study was achieved: an algorithm for predicting the efficacy of therapy in blastocystosis based on immunological parameters was developed; humoral immunity parameters were the most informative. The proportion of erroneous predictions did not exceed the preset 5% level; the algorithm requires validation on an independent sample. Keywords: infectious and parasitic diseases, Blastocystis infections, immunoglobulins, T-lymphocyte subsets, treatment outcome.
Zitieren
APA
Bodnia, I. (2026). Immunological criteria for predicting the efficacy of therapy in patients with blastocystosis. Inter Collegas, 1(13). https://doi.org/10.35339/ic.2026.13.1.bip
Vancouver
Bodnia I. Immunological criteria for predicting the efficacy of therapy in patients with blastocystosis. Inter Collegas. 2026;1(13). doi:10.35339/ic.2026.13.1.bip
BibTeX
@article{Bodnia2026,
author = {Bodnia, I.P.},
title = {Immunological criteria for predicting the efficacy of therapy in patients with blastocystosis},
journal = {Inter Collegas},
year = {2026},
volume = {1},
number = {13},
doi = {10.35339/ic.2026.13.1.bip}
}
EUVIMED